EUVIMEDOpdag EUVIMED
Crossref

THADA‐IGF2BP3 fusions detected in fine‐needle aspiration specimens of thyroid nodules: An institutional experience

Maria A Gubbiotti iD, Stefen Andrianus, Zubair Baloch

Diagnostic Cytopathology · 2023-06 · 51 (6) · 349-355

DOI: 10.1002/dc.25113 ↗

At a glance

Journal article in Diagnostic Cytopathology, 2023-06. Written by Maria A Gubbiotti and 2 co-authors. Institution: Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA. Major MEDLINE topics: Thyroid Nodule, Thyroid Neoplasms, Carcinoma, Papillary, Adenocarcinoma, Follicular. Cited 9 times so far (Crossref); 21 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Introduction

Though the clinical significance of THADA‐IGF2BP3 fusions detected in thyroid nodules preoperatively is still under investigation, the limited literature suggests these lesions are clinically low‐risk.

Methods

The pathology archives were searched from 2018 to 2022 for all thyroid nodules with a THADA‐IGF2BP3 fusion detected via ThyroSeqV3® analysis. Patient demographics and tumor characteristics were collected. Statistical analyses were performed and p < .05 was considered statistically significant. This study was approved by the institutional review board.

Results

The case cohort included 34 thyroid nodules with THADA‐IGF2BP3 fusions from 32 patients (average age—56.1 years, range: 30–86, male to female ratio—10:22). The average nodule size was 3.2 cm (range: 1.3–7.3 cm). At the time of biopsy, 21 cases were diagnosed as atypia of undetermined significance/follicular lesion of undetermined significance, 12 as follicular neoplasm/suspicious for follicular neoplasm and 1 as suspicious for malignancy. Surgical resection was performed in 29 patients (13 partial and 16 total thyroidectomies) to give a total of 31 nodules. Papillary thyroid carcinoma was diagnosed in 19/31 (61%) cases. No cases showed extrathyroidal extension or lymphovascular invasion. The remaining cases were considered either a low‐risk neoplasm or benign. Four cases of NIFTP on final surgical pathology harbored concurrent incidental papillary thyroid microcarcinoma. One patient had the THADA‐IGF2BP3 fusion detected in bilateral nodules.

Conclusions

THADA‐IGF2BP3 fusions can occur in malignant, low‐risk and benign thyroid neoplasms, where malignant neoplasms show lack of aggressive features. Therefore, such entities can be classified as clinically low risk.

Subjects

MeSH terms (MEDLINE)

Thyroid NoduleThyroid NeoplasmsCarcinoma, PapillaryAdenocarcinoma, FollicularHumansMaleFemaleBiopsy, Fine-NeedleThyroid Cancer, PapillaryRetrospective StudiesNeoplasm Proteins

Author keywords

BethesdaTHADA-IGF2BP3ThyroSeqfine-needle aspirationthyroid

Substances

THADA protein, humanNeoplasm Proteins

Authors and institutions

  • Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.

ORCID profiles: Maria A Gubbiotti

Cite

APA

Gubbiotti, M. A., Andrianus, S., & Baloch, Z. (2023). THADA‐IGF2BP3 fusions detected in fine‐needle aspiration specimens of thyroid nodules: An institutional experience. Diagnostic Cytopathology. https://doi.org/10.1002/dc.25113

Vancouver

Gubbiotti MA, Andrianus S, Baloch Z. THADA‐IGF2BP3 fusions detected in fine‐needle aspiration specimens of thyroid nodules: An institutional experience. Diagnostic Cytopathology. 2023. doi:10.1002/dc.25113

BibTeX
@article{Gubbiotti2023,
  author = {Gubbiotti, Maria A and Andrianus, Stefen and Baloch, Zubair},
  title = {THADA‐IGF2BP3 fusions detected in fine‐needle aspiration specimens of thyroid nodules: An institutional experience},
  journal = {Diagnostic Cytopathology},
  year = {2023},
  doi = {10.1002/dc.25113}
}
Start for free →